Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? — ESTIMABL2  

Low Risk Differentiated Thyroid Cancer Clinical Trial

Official title: Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?

Status Active, not recruiting

Clinical Trial Summary

Open-label randomized phase III trial, using a non-inferiority comparison design. After randomization,patients will receive either post-operative radioiodine ablation with an activity of 1.1 GBq (30 mCi) after stimulation by rhTSH, and then be followed-up (ablation group) or be followed-up (without postoperative radioiodine ablation) (follow-up group).

The objective is to assess the non-inferiority of the proportion of patients without tumor-related event evaluated at three years after randomisation in the absence of radioiodine ablation (follow-up group) compared to the ablation group, in patients with low-risk differentiated thyroid cancer treated with total thyroidectomy with or without lymph node dissection (pT1am N0 or Nx, pT1b N0 or Nx)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Low Risk Differentiated Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

• NCT number: NCT01837745
• Study type: Interventional
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: May 13, 2013
• Completion date: January 1, 2030